CohBar Stock Doubles: Company Agrees To Merge With Morphogenesis To Advance Late-Stage Oncology Candidates
CohBar Stock Doubles: Company Agrees To Merge With Morphogenesis To Advance Late-Stage Oncology Candidates
Privately-held Morphogenesis Inc has agreed to combine with CohBar Inc (NASDAQ:CWBR) in an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline.
The combined company will focus on advancing Morphogenesis' two technologies that seek to overcome the major obstacles that limit the effectiveness of current immunotherapies in treating cancer.
The combined company is expected to operate under the name "TuHURA Biosciences Inc" and to trade on The Nasdaq Capital Market. The transaction is expected to close in Q3 of 2023.
The lead asset, IFx-Hu2.0, is expected to enter Phase 2/3 registration trial as the first-line treatment for Merkel Cell Carcinoma in early 2024.
Under the terms of the merger agreement, each holder of CohBar common stock will be issued a dividend equal to approximately 3.30 shares of CohBar common stock.
On a pro forma basis, CohBar equity holders are expected to own approximately 15%, and pre-merger Morphogenesis equity holders are expected to own approximately 77%.
CohBar also entered into a $15 million PIPE, with an anticipated cash runway through 2024.
Following the merger, the combined company will be headquartered in Tampa, Florida, and the executive officers are expected to be James Bianco, as CEO, and Dan Dearborn, as CFO.
Price Action: CWBR shares are up 157.60% at $3.99 on the last check Tuesday.
Privately-held Morphogenesis Inc has agreed to combine with CohBar Inc (NASDAQ:CWBR) in an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline.
私人持有 Morphogen 已同意與 CohBar Inc (NASDAQ: CWBR) 參與一項全股交易，成立了一家結合專業知識和資源推進後期腫瘤學產品線的公司。
The combined company will focus on advancing Morphogenesis' two technologies that seek to overcome the major obstacles that limit the effectiveness of current immunotherapies in treating cancer.
合併後的公司將專注於推進Morphogenesis的兩項技術，這些技術旨在克服限制當前免疫療法治療癌症有效性的主要障礙。
The combined company is expected to operate under the name "TuHURA Biosciences Inc" and to trade on The Nasdaq Capital Market. The transaction is expected to close in Q3 of 2023.
合併後的公司預計將以 “” 的名義運營。TuHura 生物科學公司“並在納斯達克資本市場上交易。該交易預計將於2023年第三季度完成。
The lead asset, IFx-Hu2.0, is expected to enter Phase 2/3 registration trial as the first-line treatment for Merkel Cell Carcinoma in early 2024.
主要資產， ifx-HU2.0，預計將於2024年初進入2/3期註冊試驗，作爲默克爾細胞癌的一線治療方法。
Under the terms of the merger agreement, each holder of CohBar common stock will be issued a dividend equal to approximately 3.30 shares of CohBar common stock.
根據合併協議的條款，CohBar普通股的每位持有人將獲得相當於約3.30股CohBar普通股的股息。
On a pro forma basis, CohBar equity holders are expected to own approximately 15%, and pre-merger Morphogenesis equity holders are expected to own approximately 77%.
預計CohBar股權持有人將擁有約15％的股權，合併前的Morphogenesis股權持有人預計將擁有約77％的股權。
CohBar also entered into a $15 million PIPE, with an anticipated cash runway through 2024.
CohBar還簽訂了1500萬美元的PIPE，預計現金流將持續到2024年。
Following the merger, the combined company will be headquartered in Tampa, Florida, and the executive officers are expected to be James Bianco, as CEO, and Dan Dearborn, as CFO.
合併後，合併後的公司將總部設在佛羅里達州坦帕，預計執行官將是擔任首席執行官的詹姆斯·比安科和擔任首席財務官的丹·迪爾伯恩。
Price Action: CWBR shares are up 157.60% at $3.99 on the last check Tuesday.
價格走勢： 在週二的最後一張支票中，CWBR股價上漲了157.60％，至3.99美元。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧